



## **VGX Pharmaceuticals Announces Initiation of IND-enabling Toxicology Studies for Candidate DNA Vaccine Products**

**Blue Bell, PA – August 15, 2007 –**

VGX Pharmaceuticals today announced that it has initiated IND-enabling pre-clinical toxicology studies for three of its DNA plasmid-based product candidates. The candidates include vaccines for human papilloma virus for the treatment of cervical cancer (VGX-3100) and avian influenza (VGX-3400), and a therapeutic based on human growth hormone releasing hormone (VGX-3200) for cancer related cachexia. VGX is conducting the studies in combination with its patented CELLECTRA™ electroporation device and the studies will provide pre-clinical safety data for both the product candidates as well as the device in a GLP environment.

"We are pleased that our Immune Therapeutics program has entered the GLP toxicology stage and has allowed us to fully validate our dynamic vertically integrated product development program for DNA based products," stated Dr. J. Joseph Kim, President and CEO of VGX.

All three DNA plasmid-based products have previously demonstrated efficacy in various animal models. The CELLECTRA™ device delivers DNA plasmids efficiently via the application of constant-current electroporation pulses. The device has been tested extensively in research studies in a large number of different animal models, including non-human primates, establishing a broad safety, tolerability and efficacy profile.

The current toxicology studies will be completed in early 2008 and Investigational New Drug Applications (INDs) for the three products are expected to be filed in the first half of 2008.

**Cautionary Factors That May Affect Future Results** - Materials in this Press Release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on [www.vgxp.com](http://www.vgxp.com) as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

### **About VGX Pharmaceuticals**

VGX Pharmaceuticals is a biopharmaceutical company with small molecule and biologic product candidates for the treatment of infectious diseases, cancer, and inflammatory diseases. The Company's clinical development programs include PICTOVIR™ for HIV infection, which is in Phase II clinical trials, and PENNVAX™-B, a DNA vaccine for preventing HIV infection, which is in Phase I clinical trials. In addition, VGX is planning to initiate Phase I clinical studies for VGX-1027, its lead compound for inflammatory diseases. VGX's research pipeline includes a new generation of SynCon™ DNA vaccines and therapeutics as well as the CELLECTRA™ electroporator, a patented DNA delivery device. The product candidates and technology programs are protected by the Company's extensive global intellectual property portfolio. More information about VGX can be found at [www.vgxp.com](http://www.vgxp.com).

### **Company Contact:**

Kevin W. Rassas  
Senior Vice President  
Tel. 267.440.4208  
Fax 267.440.4242  
E-mail: [Rassas@vgxp.com](mailto:Rassas@vgxp.com)  
[www.vgxp.com](http://www.vgxp.com)